The company exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. Revenue is in a state of collapse, declining by 64.10% year-over-year, coupled with a devastating operating margin of -262.71%. While the current ratio of 4.86 suggests short-term liquidity, the lack of profitability and crashing top-line growth make the business model unsustainable. Technical trends are heavily bearish (10/100), and the absence of analyst coverage further underscores the lack of institutional confidence.